{"classes":[{"categories":[{"measurements":[{"comment":"Upper bound is infinity due to skew of survival data","groupId":"OG000","lowerLimit":"30.9","upperLimit":"NA","value":"35.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"The median amount of time as measured from the start of treatment until either death or progression.\n\nProgressive disease requires 1 or more of the following:\n\n* \\>=25% increase from lowest response level in serum M-protein (\\>=0.5 g/dL absolute increase) and/or urine M-component (\\>=200 mg/24hr absolute increase)\n* \\>=25% increase in the difference between involved and uninvolved FLC levels (absolute increase \\>10 mg/dL). Only for use in patients without measurable serum and M-protein levels.\n* \\>=25% increase in bone marrow plasma cell percentage (absolute percentage \\>=10%)\n* New or increase in existing bone lesions or soft tissue plasmacytomas\n* Hypercalcemia (serum calcium \\>11.5 mg/dL) due solely to the plasma cell proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG000","title":"Treatment Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the start of treatment until death or progression or until 3 years after the last participant is enrolled","title":"Median Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}